Progress in clinical trials of boron neutron capture therapy of head and neck cancers
10.3760/cma.j.issn.0254-5098.2020.08.012
- VernacularTitle:硼中子俘获治疗头颈部肿瘤临床试验进展
- Author:
Jing HE
1
;
Xiaobin TANG
;
Yuanhao LIU
;
Xiaoyi LIN
;
Xiangquan KONG
Author Information
1. 南京中硼联康医疗科技有限公司生物医药部 211102
- From:
Chinese Journal of Radiological Medicine and Protection
2020;40(8):642-647
- CountryChina
- Language:Chinese
-
Abstract:
Boron neutron capture therapy(BNCT)is an advanced radiotherapy combined with targeted therapy and heavy ion therapy. BNCT is based on the nuclear reaction 10B (n, α) 7Li that occurs when boron-10 isotopes is irradiated with neutrons of the appropriate energy to produce high-energy recoiling 7Li nuclei and α particles. The released high linear energy transfer (LET) particles have path lengths of approximately one cell diameter (5-9 μm) and deposit most of their energy within the boron-containing tumor cells. BNCT has the advantages of precise tumor targeting, less damage to normal tissue and fewer irradiation fractionations (1-3 fractionations) than conventional radiotherapy (30 fractionation). The neutrons used in BNCT are produced by reactors or accelerators. The boron drugs used in clinical trials include BPA and BSH. In this paper, we review the clinical trial status and the significant progress of BNCT for head and neck tumors. The clinical data have approved the effectiveness of BNCT in the treatment of head and neck cancer. With the technical improvement of accelerator neutron source and the development of new boron drugs, BNCT will play a more important role in the field of clinical radiotherapy in the future.
